AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6348714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 152
Study 6348714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 152
Study 6348714 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 152
Study 6348714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 31305423 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 0
Study 31305423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 0
Study 30008787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Laminaria japonica (FST) 1.5 g/day for 6 weeks
Number of subjects: 40
Study 30008787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 40
Study 25401715 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 40 mg/d)
Number of subjects: 0
Study 25401715 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10 to 20 mg/d)
Number of subjects: 0
Study 22550847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurved Siriraj Wattana Recipe
Number of subjects: 0
Study 22550847 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 0
Study 20191481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 32
Study 20191481 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 32
Study 18022546 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccines (including inactivated tumor cells, heat shock protein vaccines, anti-ganglioside antibodies)
Number of subjects: 0
Study 18022546 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to expand antitumor T lymphocytes and adoptively transfer them to patients
Number of subjects: 0
Study 15350323 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of the ICL
Number of subjects: 294
Study 11246064 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual post-discharge care in Australia (n=100)
Number of subjects: 200
Study 11246064 — intervention group
Group type: COMPARATOR
Intervention: Usual post-discharge care in Scotland (n=75)
Number of subjects: 200
Study 11246064 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual post-discharge care in Australia
Number of subjects: 200
Study 11246064 — intervention group
Group type: COMPARATOR
Intervention: Usual post-discharge care in Scotland
Number of subjects: 200
Study 9842819 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 75
Study 9842819 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 75
Study 9842819 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 75
Study 8084623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapedotomy with stapedius tendon preservation
Number of subjects: 1323
Study 8084623 — intervention group
Group type: COMPARATOR
Intervention: Stapedectomy and stapedotomy with tendon section
Number of subjects: 1323
Study 2721108 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime alone in healthy volunteers
Number of subjects: 13
Study 2721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime in ESRD
Number of subjects: 13
Study 2721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime with mezlocillin in healthy volunteers
Number of subjects: 13
Study 2721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime with mezlocillin in ESRD
Number of subjects: 13
Study 2721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Desacetyl cefotaxime in ESRD
Number of subjects: 13
Study 2721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin in ESRD
Number of subjects: 13
Study 2721108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime with mezlocillin
Number of subjects: 13
Study 31022313 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy with exposure (CBT ERP)
Number of subjects: 31
Study 31022313 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 31
Study 27810663 — intervention group
Group type: EXPERIMENTAL
Intervention: M4 group (multiple-modality exercise + mind-motor training)
Number of subjects: 127
Study 27810663 — intervention group
Group type: EXPERIMENTAL
Intervention: M4 group
Number of subjects: 127
Study 27810663 — intervention group
Group type: COMPARATOR
Intervention: M2 group (multiple-modality exercise + balance training)
Number of subjects: 127
Study 27810663 — intervention group
Group type: COMPARATOR
Intervention: M2 group
Number of subjects: 127
Study 26142612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant continuation (AD)
Number of subjects: 68
Study 26142612 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant discontinuation (C)
Number of subjects: 68
Study 22648923 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty
Number of subjects: 184
Study 22648923 — intervention group
Group type: COMPARATOR
Intervention: Non-omentoplasty
Number of subjects: 184
Study 21291529 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 211
Study 21291529 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and Tamoxifen
Number of subjects: 211
Study 18804207 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 47
Study 18804207 — intervention group
Group type: COMPARATOR
Intervention: Routine IVF (Control)
Number of subjects: 47
Study 16208050 — intervention group
Group type: COMPARATOR
Intervention: Modified Mini-Mental State Examination (MMSE) administered to Group A (non-neurological illness)
Number of subjects: 100
Study 16208050 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mini-Mental State Examination (MMSE) administered to Group B (encephalopathy)
Number of subjects: 100
Study 10599952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (600 mg + 5 microg/ml adrenaline)
Number of subjects: 30
Study 10599952 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine (600 mg + 5 microg/ml adrenaline)
Number of subjects: 30
Study 7867179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gianturco‐Roubin stent (n = 33)
Number of subjects: 66
Study 7867179 — intervention group
Group type: COMPARATOR
Intervention: Control (medical therapy only, n = 33)
Number of subjects: 66
Study 1784628 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg miglitol
Number of subjects: 2
Study 1784628 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg miglitol
Number of subjects: 2
Study 1784628 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg miglitol
Number of subjects: 2
Study 1784628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6177276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative normovolemic hemodilution with dextran 70
Number of subjects: 2
Study 6177276 — intervention group
Group type: COMPARATOR
Intervention: Conventional bank blood transfusion
Number of subjects: 2
Study 29450728 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg/day of vitamin D3
Number of subjects: 117
Study 29450728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 29961638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D intervention (patient-centred care model)
Number of subjects: 1546
Study 29961638 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1546
Study 26789872 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 75 mg
Number of subjects: 2427
Study 26789872 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg
Number of subjects: 2427
Study 26789872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2427
Study 26789872 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline (75 mg and 100 mg combined)
Number of subjects: 2427
Study 24440365 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance training
Number of subjects: 30
Study 24440365 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 30
Study 24440365 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 22052170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive timing induction chemotherapy
Number of subjects: 0
Study 22052170 — intervention group
Group type: COMPARATOR
Intervention: Standard timing induction chemotherapy
Number of subjects: 0
Study 22052170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy intensification
Number of subjects: 0
Study 22052170 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 0
Study 22052170 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 0
Study 21055713 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved renal function
Number of subjects: 401
Study 21055713 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function
Number of subjects: 401
Study 21055713 — intervention group
Group type: EXPERIMENTAL
Intervention: Any significant change in renal function (positive or negative)
Number of subjects: 401
Study 21055713 — intervention group
Group type: COMPARATOR
Intervention: Stable renal function
Number of subjects: 401
Study 17010554 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Programme (ASMP) with added exercise component for 6 weeks
Number of subjects: 182
Study 17010554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 182
Study 15769772 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based care (CBC)
Number of subjects: 364
Study 15769772 — intervention group
Group type: COMPARATOR
Intervention: Enhanced primary care (EPC)
Number of subjects: 364
Study 11991913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse specialists in Parkinson's disease
Number of subjects: 1859
Study 9808823 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcall only
Number of subjects: 0
Study 9808823 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance invitation + outcall
Number of subjects: 0
Study 9808823 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 7700742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP) 6 mumol/kg birth weight
Number of subjects: 66
Study 7700742 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy (PT) using Phillips F20T12/BB lamps
Number of subjects: 66
Study 2694745 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm Dilapan tent for 3-4 hours
Number of subjects: 450
Study 2694745 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm Dilapan tent for 16-20 hours
Number of subjects: 450
Study 31869461 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive intraoperative peritoneal lavage (EIPL)
Number of subjects: 0
Study 31869461 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 30772404 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC) intervention
Number of subjects: 96
Study 30772404 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 96
Study 28401790 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (iso-osmolar contrast media)
Number of subjects: 0
Study 28401790 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (low-osmolar contrast media)
Number of subjects: 0
Study 26159016 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Huoxue Recipe (QHR) combined with azithromycin
Number of subjects: 124
Study 26159016 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (Control)
Number of subjects: 124
Study 23806850 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg subcutaneous progesterone daily for 11 days
Number of subjects: 25
Study 23806850 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg subcutaneous progesterone daily for 11 days
Number of subjects: 25
Study 21138376 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SBE (2,000 mg of SBE/day)
Number of subjects: 4
Study 21138376 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SBE (4,000 mg of SBE/day)
Number of subjects: 4
Study 21138376 — intervention group
Group type: COMPARATOR
Intervention: Positive control (1,140 mg of pinitol/day)
Number of subjects: 4
Study 21138376 — intervention group
Group type: COMPARATOR
Intervention: Negative control (2,000 mg of lactose/day)
Number of subjects: 4
Study 20556401 — intervention group
Group type: EXPERIMENTAL
Intervention: BioDynamix ColonRing™
Number of subjects: 23
Study 20556401 — intervention group
Group type: COMPARATOR
Intervention: Standard double-stapled anastomosis
Number of subjects: 23
Study 17212641 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated recombinant interferon‐alpha and ribavirin
Number of subjects: 231
Study 15773565 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic and scapular taping to change posture
Number of subjects: 120
Study 15773565 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (not explicitly detailed)
Number of subjects: 120
Study 11866010 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg x kg(‐1) tobramycin once-daily
Number of subjects: 60
Study 11866010 — intervention group
Group type: COMPARATOR
Intervention: 3.3 mg x kg(‐1) tobramycin thrice-daily
Number of subjects: 60
Study 9674473 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP group (n=20)
Number of subjects: 40
Study 9674473 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study 7697949 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 7697949 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 2653044 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%-Pilocarpine 4% twice a day
Number of subjects: 80
Study 2653044 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice a day plus Pilocarpine 4% three times a day
Number of subjects: 80
Study 134724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (2 puffs, 0.02 mg per puff)
Number of subjects: 12
Study 134724 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline (2 puffs, 0.1 mg per puff)
Number of subjects: 12
Study 31454444 — intervention group
Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 693
Study 31454444 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy + Community Reinforcement Approach for Seniors (MET + CRA-S)
Number of subjects: 693
Study 30768121 — intervention group
Group type: EXPERIMENTAL
Intervention: BFP excision with hydrodissection (15 mL of a vasoconstricting anesthetic solution)
Number of subjects: 54
Study 30768121 — intervention group
Group type: COMPARATOR
Intervention: BFP excision with 3 mL of lidocaine 2% with epinephrine
Number of subjects: 54
Study 29154063 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (420mg divided into three equal 140-mg daily doses)
Number of subjects: 82
Study 29154063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 24684534 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg daily
Number of subjects: 24
Study 24684534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24684534 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 24
Study 23090102 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (DES group; N=25)
Number of subjects: 50
Study 23090102 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (SEVO group; N=25)
Number of subjects: 50
Study 22048580 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 35
Study 22048580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 20209981 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 28
Study 17904909 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week psychosocial self-management intervention
Number of subjects: 61
Study 17904909 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 14969841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular matrine (100 mg daily for 90 days)
Number of subjects: 120
Study 14969841 — intervention group
Group type: COMPARATOR
Intervention: Conventional liver‐protective drugs alone (control group)
Number of subjects: 120
Study 11241028 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Fourier-transform infrared (FT-IR) spectra classification
Number of subjects: 0
Study 11241028 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined absorption regions of spectra
Number of subjects: 0
Study 11241028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of four absorption regions (nu=CH, nu(as)CH(3), nuC-O (amide I), nuC-O (carbonyle))
Number of subjects: 0
Study 9205679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 5
Study 9205679 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion without ibuprofen
Number of subjects: 5
Study 9205679 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline loading after ibuprofen
Number of subjects: 5
Study 9205679 — intervention group
Group type: COMPARATOR
Intervention: Control (no ibuprofen)
Number of subjects: 5
Study 7962396 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha injection
Number of subjects: 60
Study 7962396 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group identified by serum progesterone values > 20 nmol/l and daily HCG changes > +50 IU/l/day
Number of subjects: 60
Study 7962396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without high-risk indicators
Number of subjects: 60
Study 3304782 — intervention group
Group type: EXPERIMENTAL
Intervention: Human protamine sodium insulin 0.6 mg%
Number of subjects: 7
Study 3304782 — intervention group
Group type: COMPARATOR
Intervention: Human isophane zinc insulin
Number of subjects: 7
Study 30462717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion (MSC) training intervention
Number of subjects: 13
Study 27012405 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM)
Number of subjects: 606
Study 27012405 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM) high-dose cohort
Number of subjects: 606
Study 27012405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 25656094 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 31
Study 25656094 — intervention group
Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 31
Study 25656094 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (healthy individuals)
Number of subjects: 31
Study 25656094 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (healthy individuals)
Number of subjects: 31
Study 23672380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination feedback (CB)
Number of subjects: 43
Study 23672380 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-feedback (SE)
Number of subjects: 43
Study 23672380 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 43
Study 21039597 — intervention group
Group type: EXPERIMENTAL
Intervention: SRD441 ointment
Number of subjects: 93
Study 21039597 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 93
Study 19186343 — intervention group
Group type: EXPERIMENTAL
Intervention: LI4 unilateral
Number of subjects: 22
Study 19186343 — intervention group
Group type: EXPERIMENTAL
Intervention: LI4 bilateral
Number of subjects: 22
Study 19186343 — intervention group
Group type: EXPERIMENTAL
Intervention: LI11 unilateral
Number of subjects: 22
Study 19186343 — intervention group
Group type: EXPERIMENTAL
Intervention: LI4 and LI11 combined unilateral
Number of subjects: 22
Study 19186343 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 16625109 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium containing 300 mg of iodine (Iomeron 300) at a flow rate of 3.3 mL/s
Number of subjects: 60
Study 16625109 — intervention group
Group type: COMPARATOR
Intervention: Contrast medium containing 400 mg of iodine (Iomeron 400) at a flow rate of 2.5 mL/s
Number of subjects: 60
Study 14628939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) treatment
Number of subjects: 0
Study 14628939 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of DHFR Arg-59 and DHPS Glu-540 mutations
Number of subjects: 0
Study 11134122 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol (E(2))
Number of subjects: 27
Study 11134122 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (P)
Number of subjects: 27
Study 11134122 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol (E(2)) with Progesterone (P)
Number of subjects: 27
Study 11134122 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 27
Study 9424839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation complex including 'dry' effervescent baths, magnetolaser therapy applied to the heart area, cryomassage of the abdomen.
Number of subjects: 0
Study 9424839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation complex including 'dry' effervescent baths, magnetolaser therapy applied to the heart area, cryomassage of the abdomen, plus dry air baths.
Number of subjects: 0
Study 8340879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sight of blood with decorated adhesive bandage
Number of subjects: 70
Study 8340879 — intervention group
Group type: COMPARATOR
Intervention: Sight of blood with plain adhesive bandage
Number of subjects: 70
Study 8340879 — intervention group
Group type: COMPARATOR
Intervention: No sight of blood with decorated adhesive bandage
Number of subjects: 70
Study 8340879 — intervention group
Group type: COMPARATOR
Intervention: No sight of blood with plain adhesive bandage
Number of subjects: 70
Study 8340879 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a covariate
Number of subjects: 70